Covid-19 Outbreak of new SARS-like coronavirus (Covid-19)
- Thread starter S.J.B.
- Start date
- Status
Mr. Krinkle
Bluelight Crew
- Joined
- Apr 2, 2005
- Messages
- 29,424
look at the big brains on you two
ageingpartyfiend
Bluelighter
- Joined
- Mar 5, 2011
- Messages
- 7,562
It's you who claims the superior and rare knowledge though
Mr. Krinkle
Bluelight Crew
- Joined
- Apr 2, 2005
- Messages
- 29,424
here we go again....
05/12/21
More countries are restricting AstraZeneca’s COVID vaccine as reports of blood clots mount, and a new study published in The BMJ linked the vaccine to a higher-than-expected risk of blood clots.
Brazil’s federal government on Tuesday suspended AstraZeneca’s vaccine for pregnant women after an expectant mother in Rio de Janeiro died from a stroke possibly related to the vaccine, Reuters reported. The 35-year-old woman, who was 23 weeks pregnant, died of a hemorrhagic stroke on Monday after checking into a hospital five days earlier.
The country’s federal health regulator, Anvisa, said in a statement the use of AstraZeneca’s COVID shot by pregnant women should be “immediately suspended” as authorities investigate the reported death.
“The serious adverse event of a hemorrhagic stroke was assessed as possibly related to the use of the vaccine given to the pregnant woman,” Anvisa said.
Franciele Francinato, coordinator of the Health Ministry’s vaccination program, told reporters the suspension was enacted as a precautionary measure after health regulator Anvisa issued a warning about the vaccine’s use in pregnant women.
AstraZeneca said in a statement pregnant women and those breastfeeding were excluded from clinical trials of its COVID vaccine, though animal studies did not produce evidence of harm regarding pregnancy or fetal development.
New study links AstraZeneca to blood clots
New research published in The BMJ confirmed evidence of blood clotting and found a small risk after receiving just one dose of AstraZeneca’s vaccine.
“We did, however, observe an increased rate of venous thromboembolic events, corresponding to 11 excess venous thromboembolic events per 100,000 vaccinations and including a clearly increased rate of cerebral venous thrombosis with 7 observed events versus 0.3 expected events among the 282,572 vaccine recipients.”
Researchers investigated the likelihood of blood clotting events for 282,572 people in Denmark and Norway. Using data from healthcare registries, they reviewed information on people 18 to 65 years old who received their first dose of AstraZeneca between Feb. 9 and March 11.
About 83 arterial events were found with a morbidity ratio of 0.97. Of the 83 events, researchers observed increases in intracerebral hemorrhages. This was estimated to occur 1.7 times for every 100,000 vaccinations.
The team expected to find 30 venous thromboembolic events, but found 59 with a morbidity ratio of 1.97. About 11 excess events were estimated to occur for every 100,000 vaccinations. There was also a small increased risk of pulmonary embolism, lower limb venous thrombosis and other venous thrombosis.
Researchers found 2.5 events of blood clotting in the brain for every 100,000 vaccinations, and the morbidity ratio was estimated to be 20.25 after observing seven instances of cerebral venous thrombosis, according to the study.
The morbidity ratio for any type of blood clotting disorder was 1.52, which corresponded with three excess events for every 100,000 vaccinations. About 5.1 excess bleeding events were observed for every 100,000 vaccinations.
Of the entire vaccinated cohort, there were 15 deaths in the general population. Researchers concluded that blood clotting is a very rare side effect, but the benefits of vaccination continue to outweigh the risks.
“Our study provides evidence of an excess rate of venous thromboembolism, including cerebral venous thrombosis, among recipients of the Oxford AstraZeneca COVID-19 vaccine ChAdOx1-S within 28 days of the first dose. The absolute risks of these events were, however, small,” researchers said.
Norway will not use AstraZeneca or J&J vaccines
Norway announced Tuesday it will not resume use of the AstraZeneca vaccine due to concerns of rare blood clots reported in some patients after their first dose, Reuters reported, citing local newspaper VG.
Norway’s Prime Minister Erna Solberg confirmed Wednesday the country was dropping AstraZeneca, while Johnson & Johnson (J&J) remains on hold.
An expert committee recommended Tuesday that AstraZeneca & J&J’s vaccine be dropped from Norway’s vaccination program. The committee, set up by Norwegian government, conducted a comprehensive risk assessment of the two vaccines.
“We do not recommend that the vaccines be used in the national vaccination program due to the serious side effects that have been seen,” chair of the expert committee, Lars Vorland, said at a government press conference.
AstraZeneca was suspended March 11 due to suspected severe side effects, including blood clots. The Norwegian Institute of Public Health urged April 15 that the shot be dropped entirely, but the government sought the advice of its commission on both the AstraZeneca and J&J vaccines. Norway hasn’t used the J&J vaccine, despite its approval by the European Medicines Agency (EMA).
The commission said eight cases of severe clotting in Norway had been linked to AstraZeneca’s vaccine, and four of those recipients died.
Denmark was the first country in Europe to officially drop AstraZeneca and J&J’s vaccines due to the risk of blood clots, but many countries have restricted use of the shot in certain age groups.
The EMA and World Health Organization recommend the continued use of both vaccines despite the risks of blood clots, arguing the benefits far outweigh the associated risks.
Slovakia suspends AstraZeneca after woman’s death
The country of Slovakia announced Tuesday it was suspending AstraZeneca’s vaccine for first-time vaccinations. The decision came after the country’s State Institute for Drug Control (ŠÚKL) ruled the death of a 47-year-old woman was likely connected to the shot.
In a statement issued Friday, ŠÚKL said it determined the cause of death to be related to cerebral venous sinus thrombosis (CVST), a blood-clotting disorder where clots form in the veins that drain blood from the brain.
“Genetic examination also revealed blood-clotting disorders in the patient,” the regulator said. “Due to the existence of a genetic predisposition to a thrombophilic state, an association between [the AstraZeneca jab] and subsequent venous sinus thrombosis was established as likely,” it added.
Those who already received one dose will receive a second dose of the vaccine, but those who have not been vaccinated will receive an alternative.
Two Canadian provinces halt AstraZeneca’s COVID vaccine, Ireland discontinues in people over 40
The Canadian provinces of Alberta and Ontario said Tuesday they will stop offering first doses of AstraZeneca’s vaccine, with Ontario citing evidence the risk of rare blood clots was higher than previously estimated.
Dr. David Williams, chief medical officer of health, said Tuesday the province made the decision out of an abundance of caution and due to an increase in cases of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) — a rare, potentially fatal blood clotting syndrome linked to the AstraZeneca vaccine.
According to the Ontario health ministry, as of May 8, more than 853,000 doses of the AstraZeneca vaccine were administered with a rate of roughly one case of VITT per 100,000 doses administered. The ministry said there have since been increased reports of VITT, with a rate of 1.7 per 100,000 doses administered.
Ontario’s government will review data to consider whether to use AstraZeneca’s vaccine for second doses, while preparing guidance for people who have already received their first dose.
Meanwhile, a government report on vaccination rollout across the UK revealed five suspected blood clot cases linked to AstraZeneca’s vaccine in Northern Ireland, The Belfast Telegraph reported.
People under the age of 40 are to be offered an alternative to AstraZeneca after the UK Joint Committee on Vaccination and Immunisation warned of a small risk of people suffering blood clots.
The UK’s Medicines and Healthcare Products Regulatory Agency continued to emphasize that for the vast majority of people, “the benefits of preventing serious illness and death far outweigh any risks.”
EU will not renew contract with AstraZeneca
The EU announced it has not renewed orders for AstraZeneca’s vaccine since June 2020, and made a deal to buy up to 1.8 billion doses of Pfizer-BioNTech’s vaccine.
The commission last month launched legal action against AstraZeneca for not fulfilling its contract to supply COVID vaccines and for not having a “reliable” plan to ensure timely deliveries.
Europe’s medicines regulator said May 10 it was reviewing reports of a rare nerve-degenerating disorder, known as Guillain–Barré Syndrome, in people who received AstraZeneca. The move came after the EMA confirmed a possible link last month between J&J and AstraZeneca vaccines and rare blood clots.
05/12/21
Brazil Suspends AstraZeneca Vaccine After Pregnant Woman Dies, New Study Links Vaccine to Blood Clots, More Countries Hit Pause
More countries are restricting AstraZeneca’s COVID vaccine as reports of blood clots mount, and a new study published in The BMJ linked the vaccine to a higher-than-expected risk of blood clots.
Brazil’s federal government on Tuesday suspended AstraZeneca’s vaccine for pregnant women after an expectant mother in Rio de Janeiro died from a stroke possibly related to the vaccine, Reuters reported. The 35-year-old woman, who was 23 weeks pregnant, died of a hemorrhagic stroke on Monday after checking into a hospital five days earlier.
The country’s federal health regulator, Anvisa, said in a statement the use of AstraZeneca’s COVID shot by pregnant women should be “immediately suspended” as authorities investigate the reported death.
“The serious adverse event of a hemorrhagic stroke was assessed as possibly related to the use of the vaccine given to the pregnant woman,” Anvisa said.
Franciele Francinato, coordinator of the Health Ministry’s vaccination program, told reporters the suspension was enacted as a precautionary measure after health regulator Anvisa issued a warning about the vaccine’s use in pregnant women.
AstraZeneca said in a statement pregnant women and those breastfeeding were excluded from clinical trials of its COVID vaccine, though animal studies did not produce evidence of harm regarding pregnancy or fetal development.
New study links AstraZeneca to blood clots
New research published in The BMJ confirmed evidence of blood clotting and found a small risk after receiving just one dose of AstraZeneca’s vaccine.
“We did, however, observe an increased rate of venous thromboembolic events, corresponding to 11 excess venous thromboembolic events per 100,000 vaccinations and including a clearly increased rate of cerebral venous thrombosis with 7 observed events versus 0.3 expected events among the 282,572 vaccine recipients.”
Researchers investigated the likelihood of blood clotting events for 282,572 people in Denmark and Norway. Using data from healthcare registries, they reviewed information on people 18 to 65 years old who received their first dose of AstraZeneca between Feb. 9 and March 11.
About 83 arterial events were found with a morbidity ratio of 0.97. Of the 83 events, researchers observed increases in intracerebral hemorrhages. This was estimated to occur 1.7 times for every 100,000 vaccinations.
The team expected to find 30 venous thromboembolic events, but found 59 with a morbidity ratio of 1.97. About 11 excess events were estimated to occur for every 100,000 vaccinations. There was also a small increased risk of pulmonary embolism, lower limb venous thrombosis and other venous thrombosis.
Researchers found 2.5 events of blood clotting in the brain for every 100,000 vaccinations, and the morbidity ratio was estimated to be 20.25 after observing seven instances of cerebral venous thrombosis, according to the study.
The morbidity ratio for any type of blood clotting disorder was 1.52, which corresponded with three excess events for every 100,000 vaccinations. About 5.1 excess bleeding events were observed for every 100,000 vaccinations.
Of the entire vaccinated cohort, there were 15 deaths in the general population. Researchers concluded that blood clotting is a very rare side effect, but the benefits of vaccination continue to outweigh the risks.
“Our study provides evidence of an excess rate of venous thromboembolism, including cerebral venous thrombosis, among recipients of the Oxford AstraZeneca COVID-19 vaccine ChAdOx1-S within 28 days of the first dose. The absolute risks of these events were, however, small,” researchers said.
Norway will not use AstraZeneca or J&J vaccines
Norway announced Tuesday it will not resume use of the AstraZeneca vaccine due to concerns of rare blood clots reported in some patients after their first dose, Reuters reported, citing local newspaper VG.
Norway’s Prime Minister Erna Solberg confirmed Wednesday the country was dropping AstraZeneca, while Johnson & Johnson (J&J) remains on hold.
An expert committee recommended Tuesday that AstraZeneca & J&J’s vaccine be dropped from Norway’s vaccination program. The committee, set up by Norwegian government, conducted a comprehensive risk assessment of the two vaccines.
“We do not recommend that the vaccines be used in the national vaccination program due to the serious side effects that have been seen,” chair of the expert committee, Lars Vorland, said at a government press conference.
AstraZeneca was suspended March 11 due to suspected severe side effects, including blood clots. The Norwegian Institute of Public Health urged April 15 that the shot be dropped entirely, but the government sought the advice of its commission on both the AstraZeneca and J&J vaccines. Norway hasn’t used the J&J vaccine, despite its approval by the European Medicines Agency (EMA).
The commission said eight cases of severe clotting in Norway had been linked to AstraZeneca’s vaccine, and four of those recipients died.
Denmark was the first country in Europe to officially drop AstraZeneca and J&J’s vaccines due to the risk of blood clots, but many countries have restricted use of the shot in certain age groups.
The EMA and World Health Organization recommend the continued use of both vaccines despite the risks of blood clots, arguing the benefits far outweigh the associated risks.
Slovakia suspends AstraZeneca after woman’s death
The country of Slovakia announced Tuesday it was suspending AstraZeneca’s vaccine for first-time vaccinations. The decision came after the country’s State Institute for Drug Control (ŠÚKL) ruled the death of a 47-year-old woman was likely connected to the shot.
In a statement issued Friday, ŠÚKL said it determined the cause of death to be related to cerebral venous sinus thrombosis (CVST), a blood-clotting disorder where clots form in the veins that drain blood from the brain.
“Genetic examination also revealed blood-clotting disorders in the patient,” the regulator said. “Due to the existence of a genetic predisposition to a thrombophilic state, an association between [the AstraZeneca jab] and subsequent venous sinus thrombosis was established as likely,” it added.
Those who already received one dose will receive a second dose of the vaccine, but those who have not been vaccinated will receive an alternative.
Two Canadian provinces halt AstraZeneca’s COVID vaccine, Ireland discontinues in people over 40
The Canadian provinces of Alberta and Ontario said Tuesday they will stop offering first doses of AstraZeneca’s vaccine, with Ontario citing evidence the risk of rare blood clots was higher than previously estimated.
Dr. David Williams, chief medical officer of health, said Tuesday the province made the decision out of an abundance of caution and due to an increase in cases of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) — a rare, potentially fatal blood clotting syndrome linked to the AstraZeneca vaccine.
According to the Ontario health ministry, as of May 8, more than 853,000 doses of the AstraZeneca vaccine were administered with a rate of roughly one case of VITT per 100,000 doses administered. The ministry said there have since been increased reports of VITT, with a rate of 1.7 per 100,000 doses administered.
Ontario’s government will review data to consider whether to use AstraZeneca’s vaccine for second doses, while preparing guidance for people who have already received their first dose.
Meanwhile, a government report on vaccination rollout across the UK revealed five suspected blood clot cases linked to AstraZeneca’s vaccine in Northern Ireland, The Belfast Telegraph reported.
People under the age of 40 are to be offered an alternative to AstraZeneca after the UK Joint Committee on Vaccination and Immunisation warned of a small risk of people suffering blood clots.
The UK’s Medicines and Healthcare Products Regulatory Agency continued to emphasize that for the vast majority of people, “the benefits of preventing serious illness and death far outweigh any risks.”
EU will not renew contract with AstraZeneca
The EU announced it has not renewed orders for AstraZeneca’s vaccine since June 2020, and made a deal to buy up to 1.8 billion doses of Pfizer-BioNTech’s vaccine.
The commission last month launched legal action against AstraZeneca for not fulfilling its contract to supply COVID vaccines and for not having a “reliable” plan to ensure timely deliveries.
Europe’s medicines regulator said May 10 it was reviewing reports of a rare nerve-degenerating disorder, known as Guillain–Barré Syndrome, in people who received AstraZeneca. The move came after the EMA confirmed a possible link last month between J&J and AstraZeneca vaccines and rare blood clots.
Mr. Krinkle
Bluelight Crew
- Joined
- Apr 2, 2005
- Messages
- 29,424
It's you who claims the superior and rare knowledge though
you pro-vaxxers are just mad because i don't just listen to the one-sided pushy people on your team
ageingpartyfiend
Bluelighter
- Joined
- Mar 5, 2011
- Messages
- 7,562
You don't know my stance friend tis merely your assumption - I'm 100% pro-choice
Mr. Krinkle
Bluelight Crew
- Joined
- Apr 2, 2005
- Messages
- 29,424
ageingpartyfiend
Bluelighter
- Joined
- Mar 5, 2011
- Messages
- 7,562
It's boring good evening
good evening
Mr. Krinkle
Bluelight Crew
- Joined
- Apr 2, 2005
- Messages
- 29,424
then i must apologize
but did you miss this part?
Is it fuck, lol
It's clearly a plot by the anti-vax massive to paint the lockdown crew in a bad light by insinuating that the lockdown crew plotted to make the antivaxxers look stupid ...............
Us and them, and round and round we go
Krink man, you people who are sooo woke and aware of what's happening are falling hook line and sinker for divide and conquer - congratulations
EDIT and yes plenty of the other 'side' are falling it too - the point is that the 'sides' dont exist and are artificial]... out of this thread now for my own mental health...
a guy i wasn't even addressing comes along, and starts calling me "woke" and "you people", but when i returned fire, im the one making assumptions and insults
but im sincerely so sorry for the devaluation of my contributions
cduggles
Bluelight Crew
We’ll glue our vaccination cards to our heads. 
Droppersneck
Bluelighter
The CDC has put new policies in place which effectively created a tiered system of diagnosis. Meaning, from now on, unvaccinated people will find it much easier to be diagnosed with Covid19 than vaccinated people.
Consider…
Person A has not been vaccinated. They test positive for Covid using a PCR test at 40 cycles and, despite having no symptoms, they are officially a “covid case”.
Person B has been vaccinated. They test positive at 28 cycles, and spend six weeks bedridden with a high fever. Because they never went into a hospital and didn’t die they are NOT a Covid case.
Person C, who was also vaccinated, did die. After weeks in hospital with a high fever and respiratory problems. Only their positive PCR test was 29 cycles, so they’re not officially a Covid case either.
The CDC is demonstrating the beauty of having a “disease” that can appear or disappear depending on how you measure it.
To be clear: If these new policies had been the global approach to “Covid” since December 2019, there would never have been a pandemic at all.
www.cdc.gov
Consider…
Person A has not been vaccinated. They test positive for Covid using a PCR test at 40 cycles and, despite having no symptoms, they are officially a “covid case”.
Person B has been vaccinated. They test positive at 28 cycles, and spend six weeks bedridden with a high fever. Because they never went into a hospital and didn’t die they are NOT a Covid case.
Person C, who was also vaccinated, did die. After weeks in hospital with a high fever and respiratory problems. Only their positive PCR test was 29 cycles, so they’re not officially a Covid case either.
The CDC is demonstrating the beauty of having a “disease” that can appear or disappear depending on how you measure it.
To be clear: If these new policies had been the global approach to “Covid” since December 2019, there would never have been a pandemic at all.
COVID-19 Breakthrough Case Investigations and Reporting | CDC
Information and resources to help public health departments and laboratories investigate and report COVID-19 vaccine breakthrough cases.
Droppersneck
Bluelighter
Shit I should have known to post in the covid thread. But tbf this shows how deceptive the establishment and the scamdemic stuff is to where it can’t be disputed even by the true believers. They can’t even comment on it, bc it wrecks their world view.
Nagelfar
Bluelight Crew
Like applying quantum physics to classical conditions.
Being beholden to 'peremptory norms' before the conventions in place for such rules and regulations are coherently transparent to be sensible to the demographic - is like a cross between "anarchy & hierarchy". Reminds me of Daniel Deudney's theory of the government type behind international relations diplomacy - but this would be an intrinsically intrastate and not interstate example (and so I wouldn't think "negation" would apply to terminology in this case, his word being "negarchy")
Droppersneck
Bluelighter
Okay I have to ask are you an Ebola Alt?
Solid post regardless
Nagelfar
Bluelight Crew
Am a one & only: presuming any apparent coincidence presenting myself as another would is due to some similar mix of nonstandard chemicals running alongside the neurotransmitters of my thought process & theirs. ;-jOkay I have to ask are you an Ebola Alt?
…the concoctions themselves ultimately emulating some universal writing style, tapping it through a series of so inclined individuals. One belonging to the substance as much as the user. =^]
TheLoveBandit
Retired Never Was, Coulda been wannabe
Nagelfar
Bluelight Crew
Am at first worried how (seeing the source) this comment might trickle-down and be taken by others.Typical response for a clone who hasn't been presented with their DNA source
Ah but I see it's a claim no more than I say myself above, that I belong to a different make-up than my own
Mr. Krinkle
Bluelight Crew
- Joined
- Apr 2, 2005
- Messages
- 29,424
CDC Investigating Reports of ‘Mild’ Heart Problems in Teens, Adolescents After COVID Vaccine
05/24/21The Centers for Disease Control and Prevention (CDC) is investigating reports that some teenagers and young adults vaccinated against COVID may have experienced heart problems, according to the agency’s advisory group.
The CDC’s Advisory Committee on Immunization Practices in a May 17 statement said, reports of myocarditis to date seemed to occur predominantly in adolescents and young adults, more often in males than females, more often following the second dose and typically within four days after vaccination. Most cases appeared to be “mild” and follow-up is ongoing.
Myocarditis is inflammation of the heart muscle that can lead to cardiac arrhythmia and death. According to researchers at the National Organization for Rare Disorders, myocarditis can result from infections, but “more commonly the myocarditis is a result of the body’s immune reaction to the initial heart damage.”
The CDC’s Vaccine Safety Technical (VaST) Work Group has reviewed post-authorization COVID vaccine safety data on a weekly basis since the first COVID vaccine was rolled out in the U.S. in December 2020. At the time, vaccine recipients had to be 18 years old or older.
On May 13, the CDC signed off on expanded use of Pfizer’s COVID vaccine for ages 12- to 15-year-olds. The Pfizer vaccine so far is the only COVID vaccine to have received EUA for young teens.
The VaST session on May 17 included several presentations on myocarditis following mRNA vaccines Pfizer and Moderna.The data came from the U.S. Department of Defense, the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink.
There were also brief updates from the Veteran’s Administration and the CDC’s Clinical Immunization Safety Assessment Project groups about plans for future investigation of myocarditis.
The CDC said its monitoring systems had not found more cases of myocarditis than would be expected in the population, but members of the committee on vaccinations said healthcare providers should be made aware of the reports of the “potential adverse event.”
“We look forward to seeing more data about these cases, so we can better understand if they are related to the vaccine or if they are coincidental,” said Dr. Yvonne Maldonado, chair of the American Academy of Pediatrics’s Committee on Infectious Diseases.
“Meanwhile, it’s important for pediatricians and other clinicians to report any health concerns that arise after vaccination,” Maldonado said.
As The Defender reported, details leaked from an Israeli Health Ministry report in April raised concerns among experts about a possible link between the Pfizer’s COVID vaccine and myocarditis.
The preliminary report by a committee tasked with monitoring vaccine side effects found 62 cases of myocarditis, including two deaths, in people who received the Pfizer vaccine. Fifty-six of the cases occurred after the second dose of the vaccine, and 55 cases occurred in men — most between the ages of 18 and 30.
Israel’s pandemic response coordinator, Nachman Ash, confirmed “tens of incidents” of myocarditis occurred in vaccinated people, primarily after the second dose, but emphasized the health ministry had yet to draw any conclusions.
Israeli researchers presented their findings to the Israeli Health Ministry Director-General, Pfizer, the CDC and the U.S. Food and Drug Administration.
EU regulators in May called on Pfizer and Moderna to provide additional data related to the companies’ COVID vaccines and a potential link to heart inflammation, after the agency completed a safety review of all four COVID vaccines authorized for emergency use in the EU.
Because Moderna and Pfizer use the same mRNA technology for their vaccines, European regulators asked Moderna to monitor for similar cases of heart inflammation.
On April 27, Reuters reported the U.S. Department of Defense was investigating 14 cases of heart inflammation among people who were vaccinated through the military’s health services.
A search in VAERS revealed 288 cases of pericarditis and myocarditis reported in the U.S following COVID vaccination between Dec.14, 2020 and May 14. Of the 288 cases reported, 158 cases were attributed to Pfizer, 110 cases to Moderna and 19 cases to Johnson & Johnson’s COVID vaccine.
- Status